Buscar
Femasys Inc
FEMYAñadir a la lista de seguimiento
2.560USD
0.0000.00%
Horarios del mercado 09/23, 13:36（ET）
7.73MCap. mercado
PérdidaP/E TTM
Acerca de Femasys Inc Compañía
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Perfil de Femasys Inc
Símbolo de cotizaciónFEMY
Nombre de la empresaFemasys Inc
Fecha de salida a bolsaJun 18, 2021
Director ejecutivoLee-Sepsick (Kathy)
Número de empleados69
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 18
Dirección3950 Johns Creek Court
CiudadSUWANEE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal30024
Teléfono17705003910
Sitio Webhttps://www.femasys.com/
Símbolo de cotizaciónFEMY
Fecha de salida a bolsaJun 18, 2021
Director ejecutivoLee-Sepsick (Kathy)
Ejecutivos de Femasys Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Femasys Inc?
Los cinco principales accionistas de Femasys Inc son: Ms. Kathy Lee-Sepsick
¿Cuántas instituciones poseen acciones de Femasys Inc (FEMY)?
A fecha de 2026Q1, 64 instituciones poseen acciones de Femasys Inc, con un valor de mercado combinado de aproximadamente 6.18M, lo que representa el 10.23% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1191594.00.